Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

摘要

We would like to thank D'Alessandris and colleagues for their interest in our study. We agree that following 2 negative phase Ⅲ trials of upfront bevacizumab, both with significant crossover in the placebo arms, the optimal timing of bevacizumab administration is unclear. Our study showed that the deferred use of bevacizumab to later recurrences was not associated with diminished efficacy. Additionally, we suggested that deferring bevacizumab to later recurrences may be beneficial for some, but not all patients